HDL is the major lipoprotein carrier of plasma F2-isoprostanes

Journal of Lipid Research

Volumn 50, Issue 4, 2009, Pages 716-722

  Proudfoot, Julie M ^a   Barden, Anne E ^a   Loke, Wai Mun ^a   Croft, Kevin D ^a   Puddey, Ian B ^a   Mori, Trevor A ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

FPLC; HDL oxidation; Oxidatively damaged lipid; PAF AH; PON 1

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ARACHIDONIC ACID; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; ISOPROSTANE DERIVATIVE; LINOLEIC ACID; LIPID HYDROPEROXIDE; LOW DENSITY LIPOPROTEIN; 2,2' AZOBIS(2 AMIDINOPROPANE); 2,2'-AZOBIS(2-AMIDINOPROPANE); AMIDINE; ARYLDIALKYLPHOSPHATASE; CARRIER PROTEIN; LIPID PEROXIDE; LIPOPROTEIN; OXIDIZING AGENT; PON1 PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD ANALYSIS; CHOLESTEROL BLOOD LEVEL; ENZYME ACTIVITY; ESTERIFICATION; FAST PROTEIN LIQUID CHROMATOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN LOCALIZATION; ULTRACENTRIFUGATION; ACTIVE TRANSPORT; ATHEROSCLEROSIS; BLOOD; IN VITRO STUDY;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AMIDINES; ARACHIDONIC ACID; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; BIOLOGICAL TRANSPORT, ACTIVE; CARRIER PROTEINS; F2-ISOPROSTANES; FEMALE; HUMANS; LINOLEIC ACID; LIPID PEROXIDES; LIPOPROTEINS; LIPOPROTEINS, HDL; MALE; OXIDANTS;

EID: 67449124486     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M800607-JLR200     Document Type: Article

References (48)

1. Gordon, T., W. P. Castelli, M. C. Hjortland, W. B. Kannel, and T. R. Dawber. 1977. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 62: 707-714.
2. Gordon, D. J., and B. M. Rifkind. 1989. High-density lipoproteinthe clinical implications of recent studies. N. Engl. J. Med. 321: 1311-1316.
3. Fielding, C. J., and P. E. Fielding. 1995. Molecular physiology of reverse cholesterol transport. J. Lipid Res. 36: 211-228.
4. Cuchel, M., and D. J. Rader. 2006. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation. 113: 2548-2555.
5. Navab, M., S. Y. Hama, G. M. Anantharamaiah, K. Hassan, G. P. Hough, A. D. Watson, S. T. Reddy, A. Sevanian, G. C. Fonarow, and A. M. Fogelman. 2000. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J. Lipid Res. 41: 1495-1508.
6. Barter, P. J., S. Nicholls, K. A. Rye, G. M. Anantharamaiah, M. Navab, and A. M. Fogelman. 2004. Antiinflammatory properties of HDL. Circ. Res. 95: 764-772.
7. Bowry, V. W., K. K. Stanley, and R. Stocker. 1992. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc. Natl. Acad. Sci. USA. 89: 10316-10320.
8. Klimov, A. N., K. A. Kozhevnikova, A. A. Kuzmin, A. S. Kuznetsov, and E. V. Belova. 2001. On the ability of high density lipoproteins to remove phospholipid peroxidation products from erythrocyte membranes. Biochemistry. 66: 300-304.
9. Navab, M., J. A. Berliner, G. Subbanagounder, and S. Y. Hama. 2001. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler. Thromb. Vasc. Biol. 21: 481-488.
10. Khersonsky, O., and D. S. Tawfik. 2005. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry. 44: 6371-6382.
11. Mackness, B., P. Durrington, P. McElduff, J. Yarnell, N. Azam, and M. M. Mackness. 2003. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 107: 2775-2779.
12. Marathe, G. K., G. A. Zimmerman, and T. M. McIntyre. 2003. Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J. Biol. Chem. 278: 3937-3947.
13. McIntyre, T. M., S. M. Prescott, and D. M. Stafforini. 2008. The emerging roles of PAF acetylhydrolase. J. Lipid Res. In press.
14. Stremler, K. E., D. M. Stafforini, S. M. Prescott, and T. M. McIntyre. 1991. Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates. J. Biol. Chem. 266: 11095-11103.
15. Kriska, T., G. K. Marathe, J. C. Schmidt, T. M. McIntyre, and A. W. Girotti. 2007. Phospholipase action of platelet-activating factor acetylhydrolase, but not paraoxonase-1, on long fatty acyl chain phospholipid hydroperoxides. J. Biol. Chem. 282: 100-108.
16. Stafforini, D. M., J. R. Sheller, T. S. Blackwell, A. Sapirstein, F. E. Yull, and T. M. McIntyre. 2006. Release of free F2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases. J. Biol. Chem. 281: 4616-4623.
17. Elstad, M. R., D. M. Stafforini, T. M. McIntyre, S. M. Prescott, and G. A. Zimmerman. 1989. Platelet-activating factor acetylhydrolase increases during macrophage differentiation. A novel mechanism that regulates accumulation of platelet-activating factor. J. Biol. Chem. 264: 8467-8470.
18. Prescott, S. M., G. A. Zimmerman, D. M. Stafforini, and T. M. McIntyre. 2000. Platelet-activating factor and related lipid mediators. Annu. Rev. Biochem. 69: 419-445.
19. Morrow, J. D., K. D. Hill, R. F. Burk, T. M. Nammour, K. F. Badr, and L. J. Roberts. 1990. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. USA. 87: 9383-9387.
20. Moore, K., and L. J. Roberts. 1998. Measurement of lipid peroxidation. Free Radic. Res. 28: 659-671.
21. Morrow, J. D. 2005. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler. Thromb. Vasc. Biol. 25: 279-286.
22. Shishehbor, M. H., R. Zhang, H. Medina, M. L. Brennan, D. M. Brennan, S. G. Ellis, E. J. Topol, and S. L. Hazen. 2006. Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease. Free Radic. Biol. Med. 41: 1678-1683.
23. Morrow, J. D., J. A. Awad, H. J. Boss, I. A. Blair, and L. J. Roberts. 1992. Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc. Natl. Acad. Sci. USA. 89: 10721-10725.
24. Mori, T. A., K. D. Croft, I. B. Puddey, and L. J. Beilin. 1999. An improved method for the measurement of urinary and plasma F2-isoprostanes using gas chromatography-mass spectrometry. Anal. Biochem. 268: 117-125.
25. Nourooz-Zadeh, J., J. Tajaddini-Sarmadi, and S. P. Wolff. 1994. Measurement of plasma hydroperoxide concentration by ferrous oxidation-xylenol orange assay in conjunction with triphenylphosphine. Anal. Biochem. 220: 403-409.
26. Proudfoot, J. M., K. D. Croft, I. B. Puddey, and L. J. Beilin. 1997. The role of copper reduction by alpha-tocopherol in low-density lipoprotein oxidation. Free Radic. Biol. Med. 23: 720-728.
27. Woodman, R. J., T. A. Mori, V. Burke, I. B. Puddey, G. F. Watts, and L. J. Beilin. 2002. Effects of purified eicosapentaenoic acid and docosahexaenoic acid on glycaemic control, blood pressure and serum lipids in treated-hypertensive Type 2 diabetic patients. Am. J. Clin. Nutr. 76: 1007-1015.
28. Markwell, M. A., S. M. Haas, L. L. Bieber, and N. E. Tolbert. 1978. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochem. 87: 206-210.
29. Charlton-Menys, V., Y. Liu, and P. N. Durrington. 2006. Semiautomated method for determination of serum paraoxonase activity using paraoxon as substrate. Clin. Chem. 52: 453-457.
30. Croft, K. D., J. Proudfoot, C. Moulton, and L. J. Beilin. 1991. The effect of lipoproteins on the release of some eicosanoids by stimulated human leukocytes. A possible role in atherogenesis. Eicosanoids. 4: 75-81.
31. Hou, X., L. J. Roberts, F. Gobeil, Jr., D. Taber, K. Kanai, D. Abran, S. Brault, D. Checchin, F. Sennlaub, P. Lachapelle, et al. 2004. Isomerspecific contractile effects of a series of synthetic F2-isoprostanes on retinal and cerebral microvasculature. Free Radic. Biol. Med. 36: 163-172.
32. Tang, M., T. Cyrus, Y. Yao, L. Vocun, and D. Praticò. 2005. Involvement of thromboxane receptor in the proatherogenic effect of isoprostane F2alpha-III: evidence from apolipoprotein E- and LDL receptor-deficient mice. Circulation. 112: 2867-2874.
33. Benndorf, R. A., E. Schwedhelm, A. Gnann, R. Taheri, G. Kom, M. Didié, A. Steenpass, S. Ergün, and R. H. Böge. 2008. Isoprostanes inhibit vascular endothelial growth factor-induced endothelial cell migration, tube formation, and cardiac vessel sprouting in vitro, as well as angiogenesis in vivo via activation of the thromboxane A (2) receptor: a potential link between oxidative stress and impaired angiogenesis. Circ. Res. 103: 1037-1046.
34. Nissen, S. E., T. Tsunoda, E. M. Tuzcu, P. Schoenhagen, C. J. Cooper, M. Yasin, G. M. Eaton, M. A. Lauer, W. S. Sheldon, C. L. Grines, et al. 2003. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 290: 2292-2300.
35. Oram, J. F., and J. W. Heinecke. 2005. ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol. Rev. 85: 1343-1372.
36. Bergt, C., S. Pennathur, X. Fu, J. Byun, K. O'Brien, T. O. McDonald, P. Singh, G. M. Anantharamaiah, A. Chait, J. Brunzell, et al. 2004. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc. Natl. Acad. Sci. USA. 101: 13032-13037.
37. Pennathur, S., C. Bergt, B. Shao, J. Byun, S. Y. Kassim, P. Singh, P. S. Green, T. O. McDonald, J. Brunzell, A. Chait, et al. 2004. Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J. Biol. Chem. 279: 42977-42983.
38. Zheng, L., B. Nukuna, M. L. Brennan, M. Sun, M. Goormastic, M. Settle, D. Schmitt, X. Fu, L. Thomson, P. L. Fox, et al. 2004. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest. 114: 529-541.
39. Garza, C. A., V. M. Montori, J. P. McConnell, V. K. Somers, I. J. Kullo, and F. Lopez-Jimenez. 2007. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin. Proc. 82: 159-165.
40. Stafforini, D. M. 2009. Biology of Platelet-activating Factor Acetylhydrolase (PAF-AH, Lipoprotein Associated Phospholipase A(2). Cardiovasc. Drugs Ther. 23: 73-78.
41. McCall, M. R., M. La Belle, T. M. Forte, R. M. Krauss, Y. Takanami, and D. L. Tribble. 1999. Dissociable and nondissociable forms of platelet-activating factor acetylhydrolase in human plasma LDL: implications for LDL oxidative susceptibility. Biochim. Biophys. Acta. 1437: 23-36.
42. Blatter, M. C., R. W. James, S. Messmer, F. Barja, and D. Pometta. 1993. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur. J. Biochem. 211: 871-879.
43. Raveh, O., I. Pinchuk, E. Schnitzer, M. Fainaru, Z. Schaffer, and D. Lichtenberg. 2000. Kinetic analysis of copper-induced peroxidation of HDL, autoaccelerated and tocopherol-mediated peroxidation. Free Radic. Biol. Med. 29: 131-146.
44. Nagyová, A., M. J. Krajcovicová-Kudlácková, and J. Klvanová. 2001. LDL and HDL oxidation and fatty acid composition in vegetarians. Ann. Nutr. Metab. 45: 148-151.
45. Goulinet, S., and M. J. Chapman. 1997. Plasma LDL and HDL subspecies are heterogenous in particle content of tocopherols and oxygenated and hydrocarbon carotenoids. Relevance to oxidative resistance and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 17: 786-796.
46. Navab, M., S. S. Imes, S. Y. Hama, G. P. Hough, L. A. Ross, and R. W. Bork. 1991. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J. Clin. Invest. 88: 2039-2046.
47. Mackness, B., D. Hine, Y. Liu, M. Mastorikou, and M. Mackness. 2004. Paraoxonase 1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem. Biophys. Res. Commun. 318: 680-683.
48. Nobécourt, E., S. Jacqueminet, B. Hansel, S. Chantepie, A. Grimaldi, M. J. Chapman, and A. Kontush. 2005. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia. 48: 529-538.